Email Facebook Twitter

BTG Share Chat (BTG)

Share Price: 707.00Bid: 706.50Ask: 707.00Change: -15.00 (-2.08%)Faller - Btg
Spread: 0.50Spread as %: 0.07%Open: 722.50High: 724.50Low: 703.00Yesterday’s Close: 722.00

Share Discussion for BTG

Thread View

Please login or register to post a message on Share Chat.

Posts per page:

Posts: 1,075
Dollar earnings
13 Jun '16
If we are worried about Brexit -and I am - shares with strong earnings in dollars should do well. BTG has strong dollar earnings.
Posts: 2,237
Off Topic
Opinion:Strong Buy
BTG, broker updates
18 May '16
Strong broker backing here........

BTG broker views

Date Broker Recommendation Price Old target price New target price Notes
18 May 16 Jefferies International Buy 619.75 850.00 840.00 Reiterates
18 May 16 JP Morgan Cazenove Neutral 619.75 780.00 800.00 Reiterates
18 May 16 Deutsche Bank Buy 619.75 755.00 740.00 Retains
17 May 16 Stifel Hold 619.75 - - Reiterates
17 May 16 Jefferies International Buy 619.75 850.00 850.00 Reiterates
Posts: 16
Opinion:No Opinion
Origin of BTG
17 May '16

British Technology Group was a sell off of Government research of 80's. They actually have a key patent used by Sony in the flash card but never got a penny. You will see from results that the royalties of the drugs developed by Britain best medical boffins are the biggest earner for the company and Abiaterone (brilliant drug for advanced prostatic cancer) is biggest single earner. It still has a few more years on license so perhaps half a billion in earning. Revenue growth of BTG is up 22% but nearly half of this is currency conversion. I see that the market likes the results but sadly most of the income is not being returned to shareholders but rather used in buying up other companies, perhaps at a very full price. I got my shares in BTG when they bought Protherics which I found when they were producing the anti venom for adders and my son managed to find one in the New Forest, which very kindly chose not to bite back! The Protherics buy has been cash generative to BTG. The company bought another UK company Biocompatibles, which made stents to keep blood vessels open but conversely developed a compound to seal them for the non-operative treatment of varicose veins. At some expense to company got this licensed in USA and it was to be the best thing since sliced bread. The share price doubled, I sold half but still hold my "free" shares. The income from Varithema is less than 1% of that of Abiraterome, licensed to J&J. Varithema has been a bit slow to take off (understatement of the year). The cash generated from Abiraterome and Alemtuzumab (for chronic relapsing MS) is not being returned to shareholders but rather spent buying up other promising companies. The monies spent remain on the balance sheet, the company gets bigger, may even reach the FTSE100. Think Hanson in the 80's, built the balance sheet with the earning of takeovers and the sp grew with the balance sheet until the penny dropped, followed by the sp. The two latest buys by BTG are PneuRx for COPD and Galil Medical for kidney cancer. If Varithema and the two new treatments are successful then the shares are worth £6 and, if one is a blockbuster, could even be worth £15. If there is a clinical event with just one (and that is odds on) look at £4 and if more than one is not a clinical success you would be lucky to catch 200p as sp heads rapidly South.

Caveat Emptor,

Regards, Seadoc
Posts: 2,237
Off Topic
Opinion:Strong Buy
BTG...Broker upgrades updates......
17 May '16
30m: BTG after cracking results this morning being supported by brokers,
BTG PLC BTG Deutsche Bank Buy 607.00 586.50 755.00 755.00 Reiterates
Posts: 2,237
Off Topic
Opinion:Strong Buy
BTG..Cracking Results, UPGRADE...
17 May '16
UPDATE 1 – BTG Group FY profit doubles, sees 8 – 15 pct rev growth
17-05-2016 09:34
(Adds forecast, analyst comment, share movement)

May 17 (Reuters) – British healthcare group BTG Plc said its full-year pretax profit doubled from a year earlier as sales of its interventional therapies picked up, and forecast an 8-15 percent revenue growth for the next year.

BTG shares rose as much as 2.4 percent to 600.50 pence on Tuesday morning.

BTG said it expected revenue to be in the range 485 million pounds to 515 million pounds ($703.6 million-$746.7 million) for the financial year 2017 and costs related to research and development at about 85-95 million pounds.

Jefferies analysts said the revenue forecast was as anticipated, but expected research and development expenses to go up from the company's forecast.

Analysts on average were expecting 2017 revenue of 493.6 million pounds, according to Thomson Reuters I/B/E/S.

The specialty drugmaker reported a pretax profit of 57.5 million pounds ($83.4 million) for the year ended March 31, up from 26.7 million pounds a year ago. ...

BTG's revenue rose 22 percent to 447.5 million pounds, compared with 367.8 million pounds a year ago.

The company's interventional therapies help treat blocked arteries and veins, and blocks blood supply to cancer-affected areas. BTG also makes specialty pharmaceutical products.

Interventional therapies accounted for 33.6 percent of its revenue this year, only behind the revenue the company gets from licensing its products to other drugmakers. ($1 = 0.6897 pounds)

(Reporting by Vidya L Nathan in Bengaluru, Editing by Sunil Nair) ((;; within U.S. +1 646 223 8780; outside U.S. +91 80 6749 6137;; Reuters Messaging:

Posts: 3,365
Off Topic
Opinion:No Opinion
16 May '16
misprint in my last message. Is now in the FTSE but obviously not 100 but 250
Posts: 78
Opinion:No Opinion
Ftse 100.
21 Apr '16
Oh yeah its going to join the Ftse 100.Any idea when at all?
Posts: 3,365
Off Topic
Opinion:No Opinion
10 Apr '16
Its elevation to the FTSE100 and its new female CEO who will be in select company in the FTSE (only 7) and who is pruning and paring like mad make for an exciting future. Big article in todays Times
Posts: 2,102
Off Topic
Opinion:No Opinion
breaking the silence
21 Mar '16
only to the BoD sadly who tend to use the company as personal cash machine.
Posts: 75
Off Topic
Opinion:No Opinion
16 Mar '16
Thanks for the info, makes sense, a little R&D can go a long way.
Keep the Bunsen's burning chaps.

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.